Stockscreener 앱 받기
88.64
4.26%
3.62
전일 마감가:
$85.02
열려 있는:
$89.83
하루 거래량:
1.62M
Relative Volume:
1.09
시가총액:
$6.26B
수익:
-
순이익/손실:
$-100.44M
주가수익비율:
-39.93
EPS:
-2.22
순현금흐름:
$-105.32M
1주 성능:
+29.19%
1개월 성능:
+43.64%
6개월 성능:
+352.24%
1년 성능:
+228.54%
1일 변동 폭
$84.71
$92.85
1주일 범위
$68.50
$92.85
52주 변동 폭
$13.22
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
명칭
Structure Therapeutics Inc Adr
전화
(650) 457-1978
주소
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
GPCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
88.64 | 6.01B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-02 | 개시 | Citigroup | Buy |
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-12-04 | 개시 | H.C. Wainwright | Buy |
| 2024-09-23 | 개시 | Morgan Stanley | Overweight |
| 2024-05-21 | 개시 | JP Morgan | Overweight |
| 2024-04-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2023-07-27 | 개시 | Piper Sandler | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2023-02-28 | 개시 | BMO Capital Markets | Outperform |
| 2023-02-28 | 개시 | Guggenheim | Buy |
| 2023-02-28 | 개시 | Jefferies | Buy |
| 2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Structure Therapeutics Inc Adr 주식(GPCR)의 최신 뉴스
LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling - Finviz
Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why - Finviz
Watch Structure Therapeutics CEO Stevens on Pipeline Strategy - Bloomberg.com
Structure Therapeutics Stock Surges Amid Positive Analyst Ratings - StocksToTrade
Janney Capital Management LLC Buys New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
A 10% Owner Of Structure Therapeutics Shed Shares - AOL.com
Structure Therapeutics (NASDAQ:GPCR) Trading 12.2% HigherShould You Buy? - MarketBeat
A 10% Owner Of Structure Therapeutics Shed Shares - The Motley Fool
Price Target Hike Sparks Optimism for Structure Therapeutics - StocksToTrade
Why Structure Therapeutics Shares Are Surging Now - TipRanks
Assessing Structure Therapeutics (GPCR) Valuation After Obesity Trial Progress And Genentech Licensing Deal - Sahm
Structure Therapeutics inks major GLP-1 licensing deal - MSN
The Technical Signals Behind (GPCR) That Institutions Follow - Stock Traders Daily
Can This Stock Double Again in 2026? - Finviz
VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug - sharewise.com
Genentech Licensing Deal For Oral Obesity Drug CT-996 Might Change The Case For Investing In Structure Therapeutics (GPCR) - Sahm
H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1 - Finviz
Why Structure Therapeutics Shares Are Surging Higher - TipRanks
Roche Clears Obesity Pill Legal Concerns With Structure Patent Agreement - BioSpace
Cantor Fitzgerald reiterates Structure Therapeutics stock rating at Overweight By Investing.com - Investing.com UK
Structure Therapeutics stock gets BMO Capital’s Outperform rating reaffirmed By Investing.com - Investing.com UK
Genentech makes $100M deal with South City neighbor to clear path for GLP-1 weight-loss drug - The Business Journals
Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.4%What's Next? - MarketBeat
Voya Investment Management LLC Sells 14,230 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Analysts Are Bullish on These Healthcare Stocks: Palisade Bio (PALI), Centessa Pharmaceuticals (CNTA) - The Globe and Mail
Osaic Holdings Inc. Buys 31,972 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Medical Stocks To Watch TodayDecember 8th - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Down 3.3%Here's Why - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 5.2%Here's Why - MarketBeat
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up - Eastern Progress
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 - Finviz
Structure Therapeutics stock price target raised to $90 from $60 at H.C. Wainwright - Investing.com
Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – What’s Next? - Defense World
Avoiding Lag: Real-Time Signals in (GPCR) Movement - Stock Traders Daily
GPCRStructure Therapeutics Inc ADR Stock Price and Quote - Finviz
Structure Therapeutics (NASDAQ:GPCR) Shares Gap UpStill a Buy? - MarketBeat
Why Structure Therapeutics Shares Are Under Pressure Now - TipRanks
Pharmaceutical Stocks To Follow TodayDecember 8th - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novan (NOVN) and Pfizer (PFE) - The Globe and Mail
Structure Therapeutics begins phase 1 trial of oral obesity drug By Investing.com - Investing.com India
Structure Therapeutics begins phase 1 trial of oral obesity drug - Investing.com
New once-daily obesity pill enters first human tests using amylin biology - Stock Titan
Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 8.5%Should You Sell? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Price Target Raised to $120.00 - Defense World
Mid Cap Stocks To Watch TodayDecember 8th - MarketBeat
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Evommune, Inc. (EVMN) and Eli Lilly & Co (LLY) - The Globe and Mail
Bellevue Group AG Acquires 126,812 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Birchview Capital LP Buys Shares of 36,000 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Morgan Stanley - The Globe and Mail
Structure Therapeutics stock price target raised to $120 by Citizens - Investing.com South Africa
Structure Therapeutics Inc Adr (GPCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):